Dr. Whitney Snider is the Managing Partner of MSK Ventures at Memorial Sloan Kettering Cancer Center, where she leads the investment strategy and portfolio development for high-growth, early-stage ventures arising from MSK’s innovation ecosystem, including technologies and discoveries developed at MSK or enabled by its scientific, clinical, and translational resources.
Dr. Snider’s work focuses on accelerating breakthrough innovations into real-world impact by guiding new ventures and technologies through the investment lifecycle and commercial ecosystem. She collaborates closely with investors, faculty, and industry partners to advance MSK-connected discoveries toward meaningful, patient-centric outcomes.
Prior to joining MSK, Dr. Snider spent six years at Alexandria Venture Investments, where she served as Principal and Vice President of Life Sciences, sourcing and leading strategic investments across biotech, therapeutic platforms, and emerging life science companies. Before Alexandria, she was a Principal at Inning One Ventures, overseeing investment analysis and company formation — including co-leading the formation of Ajax Therapeutics in collaboration with MSK leadership.
Earlier in her career, Dr. Snider worked in business development and management consulting, including roles at Celgene and Bain & Company’s healthcare practice. Her professional experience spans venture capital, company formation, corporate strategic alliances, and ecosystem-building initiatives.
Dr. Snider earned her MD from Tufts University School of Medicine and her MBA with High Distinction from Harvard Business School.